Libera Bio S.L.
- Home
- Companies
- Libera Bio S.L.
- Products
- Libera Bio - Model MPN - Especially ...
Libera Bio - Model MPN - Especially Monoclonal Antibodies (Mabs) Technology
FromLibera Bio S.L.
Our patented MPN Technology® enables the discovery and development of new compounds involving intracellular biologics, especially monoclonal antibodies (mAbs), to successfully engage previously undruggable targets.
Most popular related searches
monoclonal antibody
pancreatic ductal
human cancer
pancreatic adenocarcinoma
chemotherapy treatment
pancreas
chemotherapy
Libera Bio lead target is Mutated KRAS:
- KRAS is the Most Frequently Mutated Gene in Human Cancer (e.g. in 9 out of 10 Pancreatic Ductal Adenocarcinoma – PDAC)
- The presence of mutant KRAS is associated with poor prognosis and resistance to chemotherapy and targeted treatments (e.g. EGFR)
- Despite this important Unmet Medical Need, the development of effective anti-RAS therapies has been marred by more than three decades of failure
